Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a July 10 Zacks Small-Cap Research repo ...

One of the more serious side effects from immune checkpoint inhibitor (ICI) therapies for cancer is new-onset or worsened ...

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Bristol-Myers Squibb Company recently updated its ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...